1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 0,444 | 0,485 | 10.12. |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mi | Mendus - ASH 2025 update supports renewed strategy | 193 | Edison Investment Research | Mendus has presented incremental clinical data for vididencel at the American Society of Hematology (ASH) 67th Annual Meeting, involving long-term follow-up for the ADVANCE II trial. This study is testing... ► Artikel lesen | |
| 01.12. | 59 NORTH COMMUNICATIONS: NorthX Biologics achieves milestone GMP certification to manufacture vididencel - Mendus' lead cell therapy product for acute and chronic myeloid leukemias | 4 | Cision News | ||
| 01.12. | Mendus AB: Mendus Announces Large-Scale Vididencel GMP Production Milestone in Manufacturing Alliance with NorthX Biologics | 78 | GlobeNewswire (Europe) | Mendus AB (publ; IMMU.ST), a biopharmaceutical company focused on immunotherapies targeting tumor recurrence, today announced the successful establishment of large-scale GMP production of its lead product... ► Artikel lesen | |
| 27.11. | Mendus - Ovarian cancer: another shot at goal | 265 | Edison Investment Research | Mendus has reported encouraging long-term data from its Phase I ALISON trial, which is investigating its lead off-the-shelf cancer vaccine, vididencel, in high-risk ovarian cancer (OC). The latest update... ► Artikel lesen | |
| 27.11. | Mendus AB: ALISON trial long-term follow-up confirms safety, tolerability and feasibility of vididencel as an active immunotherapy in high-risk ovarian cancer | 120 | GlobeNewswire (Europe) | Mendus AB ("Mendus" publ; IMMU.ST), a biopharmaceutical company focused on immunotherapies targeting tumor recurrence, announces positive 2-year follow-up data from the ALISON Phase 1 trial. The data... ► Artikel lesen | |
| 21.11. | Edison Group: Edison Issues Report on Mendus (IMMU) | 238 | Newsfile | London, United Kingdom--(Newsfile Corp. - November 21, 2025) - Edison issues report on Mendus (OMX: IMMU).We have updated our investment view on Mendus following its expanded strategy for vididencel... ► Artikel lesen | |
| MENDUS Aktie jetzt für 0€ handeln | |||||
| 20.11. | Mendus - New strategy broadens vididencel potential | 233 | Edison Investment Research | We have updated our investment view on Mendus following its expanded strategy for vididencel to chronic myeloid leukaemia (CML) and a broader acute myeloid leukaemia (AML) population, including chemo-eligible... ► Artikel lesen | |
| 13.11. | Mendus - New strategy underway; Q325 results | 226 | Edison Investment Research | Mendus has reported its Q325 results, following its recently announced renewed strategy to broaden the potential for its lead cancer vaccine, vididencel, to include both acute myeloid leukaemia (AML)... ► Artikel lesen | |
| 13.11. | Mendus AB: Mendus AB Interim Report January - September 2025 | 91 | GlobeNewswire (Europe) | Updated clinical development strategy based on positive data
In the third quarter of 2025, Mendus shaped up its clinical development plans for the lead program vididencel in myeloid malignancies.The... ► Artikel lesen | |
| 02.10. | Mendus - New strategy to include CML alongside AML | 344 | Edison Investment Research | Mendus has announced a strategy update, unveiling plans to expand the application of vididencel beyond the current lead programme in acute myeloid leukaemia (AML), to chronic myeloid leukaemia (CML).... ► Artikel lesen | |
| 02.10. | Mendus AB: Mendus announces updated clinical strategy and operational focus | 141 | GlobeNewswire (Europe) | Vididencel to be developed as a post-remission therapy across AML risk categories and in CML
Mendus AB ("Mendus" publ; IMMU. ST), a biopharmaceutical company focused on immunotherapies targeting tumor... ► Artikel lesen | |
| 22.08. | Mendus - Steady progress throughout Q225 | 378 | Edison Investment Research | Mendus's Q225 results reflect a period of progress across the pipeline. The lead programme, vididencel in acute myeloid leukaemia (AML), remains on track to be pivotal-stage ready in H225, creating... ► Artikel lesen | |
| 21.08. | Mendus - Clinical activities on track | 361 | Edison Investment Research | Mendus has reported its Q225 results. During the period, it made continued progress on the lead programme (vididencel in acute myeloid leukaemia, AML), which remains on track to be pivotal-stage ready... ► Artikel lesen | |
| 21.08. | Mendus AB: Mendus AB Interim Report January - June 2025 | 146 | GlobeNewswire (Europe) | Expanding the vididencel opportunity
In the second quarter of 2025, Mendus reported data from the pivotal Phase 2a ADVANCE II trial at different keynote conferences, confirming that its lead product... ► Artikel lesen | |
| 23.07. | Mendus - Strengthened IP profile in ovarian cancer | 432 | Edison Investment Research | Mendus has fortified its intellectual property (IP) profile for lead candidate, vididencel, with the granting of a new US patent covering its use in ovarian cancer (OC). While the lead programme for... ► Artikel lesen | |
| 23.07. | Mendus AB: Mendus granted US patent for use of vididencel in ovarian cancer | 154 | GlobeNewswire (Europe) | Mendus AB ("Mendus" publ; IMMU. ST), a biopharmaceutical company focused on immunotherapies targeting tumor recurrence in life-threatening cancers, today announces that the United States Patent and... ► Artikel lesen | |
| 02.06. | Mendus - Another encouraging ovarian cancer update | 348 | Edison Investment Research | Mendus presented a positive clinical update for its Phase I ALISON trial in ovarian cancer at the 61st Annual American Society of Clinical Oncology conference (ASCO 2025). Importantly, the data demonstrated... ► Artikel lesen | |
| 07.05. | Mendus - No surprises in Q125 update | 330 | Edison Investment Research | Mendus's Q125 results came in as expected, with management confirming that vididencel (in acute myeloid leukaemia, AML) is on track to be pivotal-stage ready from H225. Recent highlights include regulatory... ► Artikel lesen | |
| 06.05. | Mendus - Plans falling into place for vididencel pivotal study | 459 | Edison Investment Research | Mendus's Q125 report included no surprises, with the company staying on track to secure large-scale GMP production of vididencel and Phase III readiness by H225, which we see as the most significant... ► Artikel lesen | |
| 06.05. | Mendus AB: Mendus AB Interim Report January - March 2025 | 164 | GlobeNewswire (Europe) | Phase 3 preparations and broader pipeline developments progress
In the first quarter of 2025, Mendus provided a summary of the supportive feedback from EMA and FDA related to the preparations for a... ► Artikel lesen |
1 2 Weiter >>
31 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 81,85 | -0,79 % | BioNTech: Übernahme von CureVac perfekt | BioNTech hat im Rahmen des Umtauschangebots für CureVac die Mindestbedingung erfüllt. Bis zum Ablauf der ersten Angebotsfrist wurden 184.071.410 CureVac-Aktien eingereicht, was etwa 81,74 Prozent der... ► Artikel lesen | |
| EVOTEC | 5,242 | +2,42 % | Evotec - neue Meilensteinzahlung: Bayer startet Studie zu Alport-Syndrom | Wie die Evotec SE aus Hamburg am Donnerstag meldet, hat ihr Partner Bayer AG eine Phase-2-Studie mit dem monoklonalen Antikörper BAY 3401016 gestartet hat. Der Wirkstoff zielt auf das Protein Semaphorin-3A... ► Artikel lesen | |
| BB BIOTECH | 48,600 | -0,92 % | BB Biotech im Aufwind - Zinswende treibt Biotech-Rally an | US-Zinssenkung belebt den Biotech-Sektor. BB Biotech glänzt mit starkem Quartal, vier Exits und klarer Outperformance gegenüber dem Nasdaq Biotech Index. Seit der ersten Zinssenkung der US-Notenbank... ► Artikel lesen | |
| MEDIGENE | 0,025 | -10,71 % | MEDIGENE AG stürzt ab - ich warne vor dem nächsten Desaster! | ||
| AMGEN | 271,40 | +0,54 % | Amgen Announces 2026 First Quarter Dividend | THOUSAND OAKS, Calif., Dec. 9, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that its Board of Directors declared a $2.52 per share dividend for the... ► Artikel lesen | |
| NOVAVAX | 5,760 | +0,47 % | Novavax, Inc. (NVAX): A Bull Case Theory | ||
| HEIDELBERG PHARMA | 2,820 | +1,44 % | EQS-News: Heidelberg Pharma AG: Heidelberg Pharma gibt Veränderungen im Vorstand bekannt - Dr. Dongzhou Jeffery Liu wird Mitglied des Vorstands und Vorstandsvorsitzender | EQS-News: Heidelberg Pharma AG
/ Schlagwort(e): Personalie
Heidelberg Pharma gibt Veränderungen im Vorstand bekannt - Dr. Dongzhou Jeffery Liu wird Mitglied des Vorstands und... ► Artikel lesen | |
| ILLUMINA | 115,42 | +1,55 % | Illumina, Inc.: Illumina Reports Financial Results for Third Quarter of Fiscal Year 2025 | Revenue of $1.08 billion for Q3 2025, flat compared to Q3 2024 on both a reported and constant currency basis
GAAP operating margin of 21.0% and non-GAAP operating... ► Artikel lesen | |
| 4SC | 0,161 | +7,00 % | XFRA CAPITAL ADJUSTMENT INFORMATION - 21.11.2025 | Das Instrument WI8 IT0005090300 INFRASTRUT.WIRELESS ITAL. EQUITY wird cum Kapitalmassnahme gehandelt am 21.11.2025 und ex Kapitalmassnahme am 24.11.2025 The instrument WI8 IT0005090300 INFRASTRUT.WIRELESS... ► Artikel lesen | |
| REGENERON PHARMACEUTICALS | 620,80 | +4,20 % | Regeneron Reports Promising Phase 1/2 Data Of Lynozyfic In Newly Diagnosed Multiple Myeloma | WASHINGTON (dpa-AFX) - Regeneron Pharmaceuticals Inc. (REGN) announced encouraging results from the Phase 1/2 LINKER-MM4 trial evaluating Lynozyfic (linvoseltamab) in adults with newly diagnosed... ► Artikel lesen | |
| AAP IMPLANTATE | 1,340 | -2,19 % | aap Implantate: Kapitalerhöhung per Privatplatzierung | Die aap Implantate AG hat eine Barkapitalerhöhung um 788.150 Euro beschlossen, wodurch sich das Grundkapital auf 14,7 Millionen Euro erhöht. Die Maßnahme erfolgt durch die Ausgabe von 788.150 neuen... ► Artikel lesen | |
| BIOXXMED | 0,051 | +2,00 % | HV-Termine: Hauptversammlungen bei bioXXmed, Borussia Dortmund, CureVac, elexxion, Nanofocus, NSI Asset, OTRS | Einmal jährlich müssen sich Aufsichtsrat und Vorstand einer Gesellschaft den Aktionären stellen: Die Hauptversammlung ist das höchste Organ einer Aktiengesellschaft und vergleichbarer Unternehmens-Formen.... ► Artikel lesen | |
| INOVIO PHARMACEUTICALS | 1,850 | -1,07 % | INOVIO Pharmaceuticals, Inc.: INOVIO Reports Third Quarter 2025 Financial Results and Recent Business Highlights | Completed rolling Biologics License Application (BLA) submission seeking accelerated approval for lead candidate INO-3107; requested priority review
Expect... ► Artikel lesen | |
| INFLARX | 0,915 | +0,83 % | Leerink Partners stuft Inflarx-Aktie wegen Finanzierungssorgen auf "Market Perform" herab | ||
| INTELLIA THERAPEUTICS | 8,178 | +2,17 % | Intellia Therapeutics, Inc.: Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
MENDUS AB gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 0,453 Euro und damit +4,38 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu MENDUS AB finden Sie auf Wallstreet Online.